author-photo

F. Nuzzo

National Institutes of Health

52

Papers

1201

Citations

Citation Trend

Filter By

Papers (36) Sort By

Journal Conference Others

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

2020 International Journal of Molecular Sciences
Show All
- Source
- Cite
- Save
Citations (16)
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (18)
LBA14_PRThe HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (29)
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

2018 Molecular and Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (282)
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

2017 Oncologist
Show All
- Source
- Cite
- Save
Citations (7)
C40PerTe: efficacy and safety of pertuzumab in “real life setting” for the neoadjuvant treatment of HER2-positive breast cancer patients

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
2*Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (64)